Table II.
Modulation of cell cycle and apoptosis by TMZ, MET or TMZ plus MET.
| Cell line | Sub-group | Mean (%) Sub G0 phase | Mean (%) G0/G1 phase | Mean (%) S phase | Mean (%) G2/M phase |
|---|---|---|---|---|---|
| U87-GSGS | Control | 0.08±0.02 | 62.79±3.10 | 18.91±2.30 | 18.30±1.65 |
| TMZ | 6.22±0.20 | 45.19±1.28 | 20.32±1.41 | 34.49±1.69 | |
| MET | 5.38±0.03 | 59.20±2.36 | 18.61±1.36 | 22.19±2.52 | |
| TMZ+MET | 14.77±1.09a | 22.67±3.21a | 28.43±2.84a | 48.89±3.21a | |
| C6-GSCs | Control | 0.05±0.01 | 66.43±2.89 | 25.04±1.05 | 8.53±0.39 |
| TMZ | 5.37±0.05 | 60.06±2.03 | 17.30±0.56 | 22.64±0.58 | |
| MET | 6.28±0.24 | 56.34±1.38 | 18.65±0.47 | 25.02±0.12 | |
| TMZ+MET | 19.61±0.31a | 43.09±0.45a | 31.92±0.90a | 24.99±0.14 |
The analysis of cell cycle distribution and apoptosis rate in U87-GSCs and C6-GSCs. Data is presented as the mean and are representative of three independent experiments
a
(P<0.05, compared with single agent). TMZ, temozolomid; MET, metformin; GSCs, glioma stem cells.